Menzer C, Menzies AM, Carlino MS, et al. - In the current study, 103 individuals with metastatic melanoma with rare, activating non-V600E/K BRAF mutations that were treated with either a BRAF inhibitor (BRAFi), MEK inhibitor (MEKi), or the combination were involved to determine the efficacy of targeted therapy in such patients. Patients with rare BRAF mutations could respond to targeted therapy, nevertheless, efficiency appeared to be lower in comparison with V600E mutated melanoma. Moreover, the best regimen for both V600 and non-V600 mutations appeared to be the combination of BRAFi/MEKi. However, interpretation should be performed cautiously due to the heterogeneity of individuals with modest sample sizes for some of the reported mutations.